Pfizer (PFE) Position Lowered by Beddow Capital Management Inc.

Beddow Capital Management Inc. lessened its position in shares of Pfizer (NYSE:PFE) by 7.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,965 shares of the biopharmaceutical company’s stock after selling 21,290 shares during the quarter. Pfizer comprises 4.1% of Beddow Capital Management Inc.’s holdings, making the stock its 8th biggest position. Beddow Capital Management Inc.’s holdings in Pfizer were worth $9,995,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. BlackRock Inc. increased its stake in Pfizer by 2.8% during the 4th quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after purchasing an additional 12,183,218 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Pfizer by 11.9% during the 4th quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock valued at $2,562,162,000 after purchasing an additional 7,534,957 shares in the last quarter. Stifel Financial Corp increased its stake in Pfizer by 5,413.5% during the 3rd quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after purchasing an additional 7,226,697 shares in the last quarter. American Century Companies Inc. increased its stake in Pfizer by 46.6% during the 4th quarter. American Century Companies Inc. now owns 22,539,888 shares of the biopharmaceutical company’s stock valued at $816,395,000 after purchasing an additional 7,161,892 shares in the last quarter. Finally, Boston Partners increased its stake in Pfizer by 18.4% during the 3rd quarter. Boston Partners now owns 27,741,320 shares of the biopharmaceutical company’s stock valued at $990,365,000 after purchasing an additional 4,314,466 shares in the last quarter. Hedge funds and other institutional investors own 71.65% of the company’s stock.

In related news, insider Charles H. Hill sold 42,393 shares of the stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ian C. Read sold 132,312 shares of the stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. Insiders have sold 380,349 shares of company stock worth $13,829,340 over the last three months. 0.06% of the stock is currently owned by insiders.

A number of research analysts have issued reports on PFE shares. UBS set a $42.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Morgan Stanley upped their price target on shares of Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Bank of America set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. JPMorgan Chase restated a “buy” rating on shares of Pfizer in a research note on Tuesday, January 30th. Finally, Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $40.08.

NYSE:PFE opened at $35.71 on Friday. The firm has a market capitalization of $212.46 billion, a PE ratio of 13.48, a price-to-earnings-growth ratio of 1.77 and a beta of 0.89. Pfizer has a 1-year low of $35.64 and a 1-year high of $35.80. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the prior year, the firm posted $0.69 earnings per share. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. research analysts predict that Pfizer will post 2.95 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply